Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy

Junji Uchino, Ryosuke Hirano, Naoki Tashiro, Yuji Yoshida, Shinichiro Ushijima, Takemasa Matsumoto, Keiichi Ohta, Keita Nakatomi, Koichi Takayama, Masaki Fujita, Yoichi Nakanishi, Kentaro Watanabe

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aims and Background: To evaluate the efficacy of a combination of aprepitant and conventional antiemetic therapy in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy (MEC). Methods: Patients with advanced or recurrent lung cancer who were treated with MEC regimens at the Department of Respiratory Medicine, Fukuoka University Hospital, were included and classified into the following groups: control group (treatment: 5-HT3 receptor antagonists + dexamethasone) and aprepitant group (treatment: 5-HT3 receptor antagonists + dexamethasone + aprepitant). The presence or absence of chemotherapy-induced nausea and vomiting (CINV) was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0; patients with grade 1 or above were considered positive for CINV. Food intake per day, completion of planned chemotherapy, and progression-free survival (PFS) achieved by chemotherapy were investigated. Results: The complete suppression rate of nausea in the aprepitant group was significantly higher than that in the control group (p = 0.0043). Throughout the study, the food intake in the aprepitant group was greater than that in the control group, with the rate being significantly higher, in particular, on day 5 (p = 0.003). The completion rate of planned chemotherapy was also higher in the aprepitant group (p = 0.042). PFS did not differ significantly, but tended to be improved in the aprepitant group. Conclusions: The aprepitant group showed significantly higher complete suppression of nausea, food intake on day 5, and completion of planned chemotherapy than the control group.

Original languageEnglish
Pages (from-to)4187-4190
Number of pages4
JournalAsian Pacific Journal of Cancer Prevention
Volume13
Issue number8
DOIs
Publication statusPublished - 2012

Fingerprint

aprepitant
Lung Neoplasms
Drug Therapy
Nausea
Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Control Groups
Eating
Dexamethasone
Disease-Free Survival
Vomiting
Pulmonary Medicine
Antiemetics
Terminology

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Cancer Research

Cite this

Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy. / Uchino, Junji; Hirano, Ryosuke; Tashiro, Naoki; Yoshida, Yuji; Ushijima, Shinichiro; Matsumoto, Takemasa; Ohta, Keiichi; Nakatomi, Keita; Takayama, Koichi; Fujita, Masaki; Nakanishi, Yoichi; Watanabe, Kentaro.

In: Asian Pacific Journal of Cancer Prevention, Vol. 13, No. 8, 2012, p. 4187-4190.

Research output: Contribution to journalArticle

Uchino, J, Hirano, R, Tashiro, N, Yoshida, Y, Ushijima, S, Matsumoto, T, Ohta, K, Nakatomi, K, Takayama, K, Fujita, M, Nakanishi, Y & Watanabe, K 2012, 'Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy', Asian Pacific Journal of Cancer Prevention, vol. 13, no. 8, pp. 4187-4190. https://doi.org/10.7314/APJCP.2012.13.8.4187
Uchino, Junji ; Hirano, Ryosuke ; Tashiro, Naoki ; Yoshida, Yuji ; Ushijima, Shinichiro ; Matsumoto, Takemasa ; Ohta, Keiichi ; Nakatomi, Keita ; Takayama, Koichi ; Fujita, Masaki ; Nakanishi, Yoichi ; Watanabe, Kentaro. / Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy. In: Asian Pacific Journal of Cancer Prevention. 2012 ; Vol. 13, No. 8. pp. 4187-4190.
@article{4e68e1eeb4ea4f9ab1d25a7262481dba,
title = "Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy",
abstract = "Aims and Background: To evaluate the efficacy of a combination of aprepitant and conventional antiemetic therapy in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy (MEC). Methods: Patients with advanced or recurrent lung cancer who were treated with MEC regimens at the Department of Respiratory Medicine, Fukuoka University Hospital, were included and classified into the following groups: control group (treatment: 5-HT3 receptor antagonists + dexamethasone) and aprepitant group (treatment: 5-HT3 receptor antagonists + dexamethasone + aprepitant). The presence or absence of chemotherapy-induced nausea and vomiting (CINV) was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0; patients with grade 1 or above were considered positive for CINV. Food intake per day, completion of planned chemotherapy, and progression-free survival (PFS) achieved by chemotherapy were investigated. Results: The complete suppression rate of nausea in the aprepitant group was significantly higher than that in the control group (p = 0.0043). Throughout the study, the food intake in the aprepitant group was greater than that in the control group, with the rate being significantly higher, in particular, on day 5 (p = 0.003). The completion rate of planned chemotherapy was also higher in the aprepitant group (p = 0.042). PFS did not differ significantly, but tended to be improved in the aprepitant group. Conclusions: The aprepitant group showed significantly higher complete suppression of nausea, food intake on day 5, and completion of planned chemotherapy than the control group.",
author = "Junji Uchino and Ryosuke Hirano and Naoki Tashiro and Yuji Yoshida and Shinichiro Ushijima and Takemasa Matsumoto and Keiichi Ohta and Keita Nakatomi and Koichi Takayama and Masaki Fujita and Yoichi Nakanishi and Kentaro Watanabe",
year = "2012",
doi = "10.7314/APJCP.2012.13.8.4187",
language = "English",
volume = "13",
pages = "4187--4190",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "8",

}

TY - JOUR

T1 - Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy

AU - Uchino, Junji

AU - Hirano, Ryosuke

AU - Tashiro, Naoki

AU - Yoshida, Yuji

AU - Ushijima, Shinichiro

AU - Matsumoto, Takemasa

AU - Ohta, Keiichi

AU - Nakatomi, Keita

AU - Takayama, Koichi

AU - Fujita, Masaki

AU - Nakanishi, Yoichi

AU - Watanabe, Kentaro

PY - 2012

Y1 - 2012

N2 - Aims and Background: To evaluate the efficacy of a combination of aprepitant and conventional antiemetic therapy in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy (MEC). Methods: Patients with advanced or recurrent lung cancer who were treated with MEC regimens at the Department of Respiratory Medicine, Fukuoka University Hospital, were included and classified into the following groups: control group (treatment: 5-HT3 receptor antagonists + dexamethasone) and aprepitant group (treatment: 5-HT3 receptor antagonists + dexamethasone + aprepitant). The presence or absence of chemotherapy-induced nausea and vomiting (CINV) was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0; patients with grade 1 or above were considered positive for CINV. Food intake per day, completion of planned chemotherapy, and progression-free survival (PFS) achieved by chemotherapy were investigated. Results: The complete suppression rate of nausea in the aprepitant group was significantly higher than that in the control group (p = 0.0043). Throughout the study, the food intake in the aprepitant group was greater than that in the control group, with the rate being significantly higher, in particular, on day 5 (p = 0.003). The completion rate of planned chemotherapy was also higher in the aprepitant group (p = 0.042). PFS did not differ significantly, but tended to be improved in the aprepitant group. Conclusions: The aprepitant group showed significantly higher complete suppression of nausea, food intake on day 5, and completion of planned chemotherapy than the control group.

AB - Aims and Background: To evaluate the efficacy of a combination of aprepitant and conventional antiemetic therapy in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy (MEC). Methods: Patients with advanced or recurrent lung cancer who were treated with MEC regimens at the Department of Respiratory Medicine, Fukuoka University Hospital, were included and classified into the following groups: control group (treatment: 5-HT3 receptor antagonists + dexamethasone) and aprepitant group (treatment: 5-HT3 receptor antagonists + dexamethasone + aprepitant). The presence or absence of chemotherapy-induced nausea and vomiting (CINV) was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0; patients with grade 1 or above were considered positive for CINV. Food intake per day, completion of planned chemotherapy, and progression-free survival (PFS) achieved by chemotherapy were investigated. Results: The complete suppression rate of nausea in the aprepitant group was significantly higher than that in the control group (p = 0.0043). Throughout the study, the food intake in the aprepitant group was greater than that in the control group, with the rate being significantly higher, in particular, on day 5 (p = 0.003). The completion rate of planned chemotherapy was also higher in the aprepitant group (p = 0.042). PFS did not differ significantly, but tended to be improved in the aprepitant group. Conclusions: The aprepitant group showed significantly higher complete suppression of nausea, food intake on day 5, and completion of planned chemotherapy than the control group.

UR - http://www.scopus.com/inward/record.url?scp=84873695492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873695492&partnerID=8YFLogxK

U2 - 10.7314/APJCP.2012.13.8.4187

DO - 10.7314/APJCP.2012.13.8.4187

M3 - Article

C2 - 23098425

AN - SCOPUS:84873695492

VL - 13

SP - 4187

EP - 4190

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 8

ER -